G-treeBNT files IND with MFDS for Phase IIB/III clinical trial of RGN-259 for dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. announced that its strategic partner, G-treeBNT Co. Ltd., has filed an IND with the Korean Ministry of Food and Drug Safety for a Phase IIB/III clinical trial with RGN-259 (designated GBT-201 in Korea and the licensed Pan Asia territory) for the treatment of patients with dry eye syndrome.



from The Medical News http://www.news-medical.net/news/20141229/G-treeBNT-files-IND-with-MFDS-for-Phase-IIBIII-clinical-trial-of-RGN-259-for-dry-eye-syndrome.aspx